Future research can explore the molecular mechanism of multiple primary cancers (such as the coexistence mode of RET/RAS/BRAF mutation) and evaluate the cost effectiveness of calcitonin screening to optimize clinical practice. This evidence concerns the gene CALCA and cancer.